This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Olaf Stüve, MD, PhD; Todd N. Eagar, PhD; Elliot M. Frohman, MD, PhD; Petra D. Cravens, PhD

Arch Neurol. 2007;64(10):1385-1386.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of the Archives, Bar-Or and coworkers¹ report on a successful attempt to induce antigen-specific tolerance with a DNA encoding myelin basic protein (MBP) vaccine in patients with multiple sclerosis (MS). Two questions immediately arise: (1) why vaccinate patients with MS with a self antigen, and (2) why use a DNA plasmid vaccine?

Multiple sclerosis is the most common inflammatory, demyelinating, and neurodegenerative disorder of the central nervous system (CNS) in humans. A pathological hallmark of MS is the infiltration of leukocytes into the brain and spinal cord. Not surprisingly, controlling the migration of T cells, B cells, and other immunocompetent myeloid cells into the brain and spinal cord has been a major target of drug development over the last 15 years. Substantial evidence for the role of myelin-specific T . . . [Full Text of this Article]

AUTHOR INFORMATION



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

"Groovy" Vaccine for Melanoma--But Which Groove?
Nehlsen-Cannarella
JCO 2008;26:6009-6010.
FULL TEXT